Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
1. A method of treating a patient diagnosed with a glioma characterized by an IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising a total of 150 mg of olutasidenib twice per day (BID).
2. The method of claim 1 , wherein the olutasidenib is administered as a single agent.
3. The method of claim 1 , wherein the glioma is characterized by an R132 IDH1 mutation.
4. The method of claim 3 , wherein the R132 IDH1 mutation is selected from R132C, R132H, R132G, R132S, and R132L.
5. The method of claim 1 , wherein the glioma is relapsed/refractory mIDH1 glioma.
6. The method of claim 1 , wherein the patient has previously received temozoloide to treat a mIDH1 glioma prior to administration of the olutasidenib to the patient.
7. The method of claim 1 , wherein the olutasidenib is administered to the patient in need thereof in a tablet or capsule oral unit dosage form on consecutive days throughout a course of treatment of at least 15 consecutive days.
8. A method of treating a patient diagnosed with a glioma having a susceptible IDH1 mutation comprising orally administering 150 mg of olutasidenib twice per day (BID) to the patient in need thereof.
9. The method of claim 8 , wherein the patient is diagnosed with a WHO Grade II or III glioma.
10. The method of claim 8 , wherein the patient is diagnosed with WHO Grade IV glioma.
11. The method of claim 8 , wherein the IDH1 mutation is a R132X mutation.
12. The method of claim 11 , wherein the IDH1 mutation is selected from the group consisting of R132C, R132G, R132S, R132H and R132L.
13. The method of claim 8 , wherein the glioma is a histologically or cytologically-confirmed IDH1 R132X gene-mutated advanced solid tumor.
14. The method of claim 8 , wherein the glioma is histologically or cytologically confirmed IDH1 gene-mutated advanced glioma, and a diagnosis of glioblastoma multiforme with confirmed IDH1 gene-mutated disease with first or second recurrence.
15. The method of claim 8 , wherein the patient is treated by administering the olutasidenib to the patient for at least 2 weeks.
16. The method of claim 13 , wherein the patient is treated by administering the olutasidenib for 0.9-9.4 months.
17. The method of claim 8 , wherein the patient is at least 18 years of age with a documented IDH1 gene-mutated malignancy based on an FDA approved test.
18. The method of claim 17 , wherein the patient meets one or more of the following inclusion criteria prior to treatment:
a. recovered to ≤Grade 2 or baseline toxicity (except alopecia) from prior therapy (per CTCAE v 4.03);
b. Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
c. adequate bone marrow function demonstrated by one or more of the following: absolute neutrophil count (ANC) ≥1.5×109/L without any growth factors in prior 7 days and Hemoglobin ≥8.0 g/dL (with or without transfusion support); platelet count ≥75×109/L (with or without transfusion support); and platelet count ≥100×109/L (with or without transfusion support)); and
d. adequate hepatic function demonstrated by one or more of the following aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])≤2.5× institutional upper limit of normal (ULN), or for patients with suspected malignancy related elevations, <5×ULN; and Total bilirubin ≤1.5×ULN, or for patients with suspected malignancy related elevation <3× institutional upper limit of normal); and
e. adequate renal function demonstrated by creatinine clearance per Cockcroft-Gault equation of ≥60 mL/min).
19. A method of treating an adult patient diagnosed with a glioma having a susceptible IDH1 mutation comprising orally administering 150 mg of olutasidenib twice per day (BID) to the patient in need thereof.